Atrial fibrillation: Maintaining stability of sinus rhythm or ventricular rate control? The need for prospective data: The PIAF trial

PACE - Pacing and Clinical Electrophysiology

Volumn 20, Issue 8 I, 1997, Pages 1989-1993

  Hohnloser, Stefan H ^a   Kuck, Karl Heinz ^b  

^a Division of Cardiology   (Germany)

^b NONE

Author keywords

Anticoagulation; Atrial fibrillation; Cardioversion; Prospective study; Rate control

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; DILTIAZEM; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CARDIOVERSION; CLINICAL PROTOCOL; CLINICAL TRIAL; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; PROGNOSIS; SINUS RHYTHM; THROMBOEMBOLISM; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CALCIUM CHANNEL BLOCKERS; DILTIAZEM; ELECTRIC COUNTERSHOCK; FEMALE; GERMANY; HEART RATE; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN;

EID: 0030854510     PISSN: 01478389     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8159.1997.tb03606.x     Document Type: Article

References (13)

1. Kannel WB, Wolf PA. Epidemiology of atrial fibrillation. In RH Falk, PJ Podrid (eds.): Atrial Fibrillation. New York, Raven Press, 1992, pp. 81-92.
2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham study. Stroke 1992; 22:983-988.
3. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med 1994; 154:1449-1457.
4. Carson PE, Johnson GR, Dunkman WB, et al. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. Circulation 1993; 87(supplVI):VI-102-110.
5. Middlekauf HR, Stevenson WG, Stevenson LW. Prognostic significance of atrial fibrillation in advanced heart failure. Circulation 1991; 84:40-48.
6. Coplen SE, Antman EM, Berlin JA, et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. Circulation 1990; 82:1106-1116.
7. Flaker GC, Blackshear JL, McBride R, et al. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation: The Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 1992; 20:527-532.
8. The National Heart, Lung, and Blood Institute Working Group on Atrial Fibrillation. Atrial fibrillation: Current understandings and research imperatives. J Am Coll Cardiol 1993; 22: 1830-1834.
9. Roth A, Harrison E, Mitani G, et al. Efficacy and safety of medium- and high-dose dilatiazem alone and in combination with digoxin for control of heart rate at rest and during exercise in patients with chronic atrial fibrillation. Circulation 1986; 316-324.
10. Steinberg JS, Katz RJ, Bren GB, et al. Efficacy of oral diltiazem to control ventricular response in chronic atrial fibrillation at rest and during exercise. J Am Coll Cardiol 1987; 9:405-411.
11. Lundström T, Ryden L. Ventricular rate control and exercise performance in chronic atrial fibrillation: Effects of diltiazem and verapamil. J Am Coll Cardiol 1990; 16:86-90.
12. Williason BD, Man KC, Daoud E, et al. Radiofrequency catheter modification of atrioventricular conduction to control the ventricular rate during atrial fibrillation. N Engl J Med 1994; 331:910-917.
13. Hohnloser SH. Indications and limitations of class II and III drugs in atrial fibrillation. PACE 1994; 1019-1025.